Prime Medicine Stock Price, News & Analysis

Prime Medicine (Nasdaq: PRME) has announced a strategic focus on high-value programs in its pipeline. The company is prioritizing:

• Two programs for chronic granulomatous disease (CGD), including PM359 for p47phox CGD and a new program for X-linked CGD
• A collaboration with Bristol Myers Squibb for ex vivo T-cell therapies
• A liver lipid nanoparticle program for Wilson's Disease
• Two strategies for Cystic Fibrosis treatment

Prime Medicine expects to share initial clinical data from its CGD trial in 2025 and new preclinical data for Wilson's Disease in Q4 2024. The company aims to file an IND/CTA for Wilson's Disease in 1H 2026. With the Bristol Myers Squibb collaboration and cost savings, Prime Medicine anticipates extending its cash runway into 1H 2026.

Prime Medicine (Nasdaq: PRME) has announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY) to develop reagents for next-generation ex vivo T-cell therapies. The collaboration combines Prime Medicine's gene editing capabilities with Bristol Myers Squibb's expertise in cell therapy development and commercialization.

Key points of the agreement include:

• Prime Medicine to receive $110 million upfront ($55 million payment and $55 million equity investment)
• Potential for over $3.5 billion in milestones ($1.4 billion in development, $2.1 billion in commercialization)
• Prime Medicine to design optimized Prime Editor reagents, including those using PASSIGE™ technology
• Bristol Myers Squibb responsible for development, manufacturing, and commercialization

The collaboration aims to expand Prime Editing technology beyond rare genetic diseases, potentially addressing unmet needs in immunological diseases and cancer.

Prime Medicine (Nasdaq: PRME), a biotechnology company focused on one-time curative genetic therapies, has announced its participation in several upcoming investor conferences in September 2024. These include:

1. Morgan Stanley Global Healthcare Conference on September 4 in New York
2. Wells Fargo Healthcare Conference on September 5 in Boston
3. Cantor Global Healthcare Conference on September 17 in New York
4. Chardan's Genetic Medicines Conference on September 30 in New York

The company will engage in fireside chats, panel discussions, and investor meetings during these events. Live audio webcasts of the presentations will be available on Prime Medicine's website, with replays accessible for 90 days after each event.

Prime Medicine (Nasdaq: PRME) reported Q2 2024 financial results and provided business updates. Key highlights include:

1. FDA clearance for PM359, a Prime Editor for chronic granulomatous disease (CGD), to enter clinical trials.
2. Promotion of Dr. Mohammed Asmal to Chief Medical Officer.
3. Advancing multiple programs across core focus areas.
4. R&D expenses increased to $43.1 million from $34.6 million in Q2 2023.
5. Net loss widened to $55.3 million from $42.4 million in Q2 2023.
6. Cash position of $176.4 million as of June 30, 2024.

The company anticipates initial clinical data for PM359 in 2025 and plans to advance several programs in hematology, immunology, liver, ocular, and neuromuscular areas.

Prime Medicine, a biotechnology firm traded on Nasdaq under the symbol PRME, announced that CEO Keith Gottesdiener will present at two upcoming investor conferences. The first presentation will be at the Jefferies Healthcare Conference on June 5, 2024, at 1:30 p.m. ET in New York, NY. The second presentation will be at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 2:00 p.m. ET in Miami Beach, FL. Live audio webcasts of both events will be available in the 'Events & Presentations' section on the company's website, with replays accessible for 90 days post-event.

Prime Medicine, Inc. (Nasdaq: PRME) will have Allan Reine, M.D., Chief Financial Officer, participating in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024.

The company is focused on delivering innovative one-time curative genetic therapies, with the event allowing investors to gain insights into Prime Medicine's future endeavors.

Prime Medicine, Inc. (Nasdaq: PRME) reported financial results for Q1 2024, highlighting FDA clearance of its first-ever IND application for PM359 for CGD treatment. They also presented new preclinical data demonstrating Prime Editing technology's potential and appointed Tony Coles, M.D., as a senior advisor. The company is focused on advancing its pipeline programs and strengthening its Prime Editing platform.

Prime Medicine, Inc. presents preclinical data showing PM359's ability to correct CGD mutation, with FDA clearance for Phase 1/2 trial. CGD is a rare disease causing severe infections. PM359 demonstrated high correction rates, restored neutrophil function, and clinical-scale production of edited cells.

Prime Medicine, Inc. (Nasdaq: PRME) will participate in the 27th Annual Milken Institute Global Conference with its CEO, Dr. Keith Gottesdiener, discussing cutting-edge technologies and scientific breakthroughs. The panel aims to offer insights into the future and will be livestreamed on May 8, 2024.